FindTrial
Sign In

Efficacy assessment of ceftriaxone therapy in patients with amyotrophic lateral sclerosis. - ND

Efficacy assessment of ceftriaxone therapy in patients with amyotrophic lateral sclerosis. - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-004165-17-IT
Enrollment
Unknown
Registered
2007-10-15
Start date
2007-09-25
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis (ALS) MedDRA version: 6.1 Level: PT Classification code 10002026

Interventions

Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Ceftriaxone Concentration unit: g gram(s) Concentration type: equal Concentration number: 2-

Sponsors

AZIENDA OSPEDALIERA PISANA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a. definitive ALS, probable or probable with laboratory support; b. age > 18 years; c. disease duration =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: a. motoneuron disease except ALS; b. poor compliance with previous treatment; c. patients involved in other clinical trials; d. patients with history of sensitivity or intolerance to cephalosporins.

Design outcomes

Primary

MeasureTime frame
Main Objective: Assessment of the effects of intravenous administration in patients with ALS.;Secondary Objective: Assessment of the safety of intravenous administration in patients with ALS.;Primary end point(s): Assessment of survival.—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026